Die Bedeutung der Immunonkologie in der onkologischen Rehabilitation – Präsentation und Beurteilung anhand dreier Patientenfälle
GMS Onkologische Rehabilitation und Sozialmedizin; 10:Doc01 · 01.03.2019 · 1-1
DOI: 10.3205/ors000036 ↗Kurz gefasst
Fachartikel in der Zeitschrift GMS Onkologische Rehabilitation und Sozialmedizin; 10:Doc01, erschienen am 01.03.2019. Verfasst von Hass und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The introduction of checkpoint inhibitors revolutionized treatment especially in difficult-to-treat patients (e.g. melanoma, lung cancer). Reasonable to a fast admission of these drugs for many other cancers in the last few months physicians in rehabilitation centers will be faced with the new side effects and their impact on working life by these drugs. Casereports: By means of three case reports the impact of the checkpoint inhibitors for work ability as well as the potential new side effects and health risk, e.g. hypophysitis mimicry fatigue or autoimmune hepatitis, are discussed.
Conclusions
Treatment using checkpoint inhibitors shows promising results especially in patients with difficult-to-treat cancers. In our opinion these drugs will not only lead to a significant better overall survival in some cancer patients but also may influence work ability and daily treatment of specific side effects in rehabilitation centers.
Schlagwörter
Zitieren
APA
Hass, G, & H. (2019). Die Bedeutung der Immunonkologie in der onkologischen Rehabilitation – Präsentation und Beurteilung anhand dreier Patientenfälle. GMS Onkologische Rehabilitation und Sozialmedizin; 10:Doc01, 1-1. https://doi.org/10.3205/ors000036
Vancouver
Hass, G, H.. Die Bedeutung der Immunonkologie in der onkologischen Rehabilitation – Präsentation und Beurteilung anhand dreier Patientenfälle. GMS Onkologische Rehabilitation und Sozialmedizin; 10:Doc01. 2019:1-1. doi:10.3205/ors000036
BibTeX
@article{Hass2019,
author = {Hass and G and H.},
title = {Die Bedeutung der Immunonkologie in der onkologischen Rehabilitation – Präsentation und Beurteilung anhand dreier Patientenfälle},
journal = {GMS Onkologische Rehabilitation und Sozialmedizin; 10:Doc01},
year = {2019},
pages = {1--1},
doi = {10.3205/ors000036}
}
EUVIMED